Nucleix Cancer Detection Company Raises $5M

June 17, 2014 | The Israeli cancer screening company Nucleix raised $5 million in an investment round led by OrbiMed Advisers Israel, according to a “Globes” report. The $5 million raised in the current financing round is added on to the previous $3 million raised from private investors to develop the company’s early stage detection mechanism for bladder cancer. Nucleix was founded by Elon Ganor, who is best known for leaving the IT field in 2006 after founding and managing MagicJack VocalTec and for his diagnostic companies that were founded in the 1980s. Nucleix hopes to use epigenetics to pinpoint cancer cells that show signs of growth, including about 15 small changes in cell’s DNA that help differentiate a healthy cell from a cancerous one.